http://www.evrs.eu/medias/2005/congress/Does-Using-Intravitreal-Triamcinolone-Acetonide-During-ILM-Peeling-Affect-the-Outcome-of-Macular-Hole-Surgery.swf

Murat Karacorlu, Hakan Ozdemir, Serra Arf Karacorlu

Purpose:

To evaluate functional and anatomical outcome of triamcinolone acetonide assisted internal limiting membrane (ILM) peeling in patients with macular hole.

Methods:

Fifteen eye of 15 consecutive patients were identified with stage 3 and 4 idiopathic macular holes, who underwent triamcinolone acetonide assisted ILM peeling for macular hole. These were matched retrospectively with 15 eyes of 15 patients with stage 3 and 4 idiopathic macular holes of less than 6 months duration, who underwent macular hole surgery with ILM peel augmented with indocyanine green (ICG). Functional and anatomical outcomes were compared between two groups.

Results:

There were no significant differences between the two groups with reference to demographic features of age, sex, staging of the macular holes and the proportion subsequently undergoing cataract surgery. The hole closure rate was 100% in both group at primary operation. There was a significant improvement in Snellen and Logmar visual acuity in both groups. These differences in visual outcome between the groups were not statistically significant.

Conclusion:

Our data showed similar outcomes for patients with macular hole where ICG has been used when compared to patients where triamcinolone acetonide has been used for ILM peeling.

Take-home message:

Triamcinolone acetonide is as useful as ICG for ILM peeling and there is no adverse affect on hole closur caused by triamcinolone.